Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D

BACKGROUND: Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer treatment but responses vary with patients, for reasons that are still not very clear. Interferon-α (IFN-α) is also used as a therapeutic agent for bladder cancer treatment but the response rate is low. It...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiang, Zhe, Zhou, Zong-yuan, Peng, Ting, Jiang, Pu-zi, Shi, Nan, Njoya, Emmanuel Mfotie, Azimova, Bahtigul, Liu, Wan-li, Chen, Wei-hua, Zhang, Guo-lin, Wang, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260752/
https://www.ncbi.nlm.nih.gov/pubmed/30482227
http://dx.doi.org/10.1186/s13046-018-0971-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260752/
https://www.ncbi.nlm.nih.gov/pubmed/30482227
http://dx.doi.org/10.1186/s13046-018-0971-4

Ejemplares similares